Catalyst
Slingshot members are tracking this event:
FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Olaratumab, Advanced Soft Tissue Sarcoma, Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review
